Nykredit A/S’s Arcus Biosciences RCUS Stock Holding History

Nykredit A/S’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$134K	Buy	+4,343	New	+$107K	﹤0.01%	1194

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's RCUS Position: Q2 2026 in Review

Nykredit A/S opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 4,343 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #1194 among its holdings.

152 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Nykredit A/S held 4,343 shares of Arcus Biosciences worth $134K as of Q2 2026.
Arcus Biosciences was a new Nykredit A/S position in Q2 2026.
Arcus Biosciences made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1194 holding.
152 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.